PML and acute promyelocytic leukemia: In APL clonal evolution resulting in by acquisition of mutations leading to ATO resistance (such as the recently reported PML B2 domain mutation) are rare as is demonstrated by the few cases in which this has been reported [18, 19] and the ability of ATO to induce molecular remission in the majority of patients with multiple relapses even after prior exposure to ATO.